|
Oct 9
|
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
|
|
Sep 25
|
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
|
|
Sep 4
|
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
|
|
Sep 3
|
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
|
|
Sep 2
|
Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
|
|
Jul 25
|
Cyclacel Pharmaceuticals (CYCC) Upgraded to Strong Buy: Here's What You Should Know
|
|
Jun 26
|
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
|
|
May 15
|
Cyclacel Pharmaceuticals Inc (CYCC) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
|
|
May 14
|
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
|
|
May 8
|
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
|
|
May 2
|
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
|
|
Apr 30
|
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
|
|
Apr 25
|
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Is Expected To Breakeven In The Near Future
|
|
Apr 1
|
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
|
|
Mar 20
|
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript
|
|
Mar 19
|
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
|
Mar 13
|
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 7
|
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
|
|
Mar 6
|
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
|
|
Jan 8
|
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
|